📊 DNABW Key Takeaways
Is DNABW a Good Investment? Thesis Analysis
Ginkgo Bioworks is a pre-commercial biotech company burning substantial cash with significant losses and negative margins across all profitability measures. While the company maintains adequate liquidity with $167.2M in cash and a 4.92x current ratio, the severe operating losses (-$315.3M), deteriorating revenue (-25.1% YoY), and substantial negative free cash flow (-$178.7M) indicate the business model has not yet achieved commercial viability. At the current cash burn rate, the company has limited runway without significant operational improvements or additional capital raises, presenting substantial execution risk.
Why Buy DNABW? Key Strengths
- Strong liquidity position with $167.2M cash and 4.92x current ratio provides runway for operations
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk
- Modest insider activity suggests some level of confidence from company leadership
DNABW Investment Risks to Consider
- Severe operating losses of -$315.3M with -185.3% operating margin indicate business is far from profitability
- Revenue declined 25.1% year-over-year despite being pre-commercial, suggesting market execution challenges
- Negative free cash flow of -$178.7M annually will deplete cash reserves within approximately 12-15 months without improvement
- Diluted EPS of -$5.64 and negative ROE/ROA indicate value destruction for shareholders
- No gross profit reporting suggests potential product costing or revenue recognition issues
Key Metrics to Watch
- Revenue growth trajectory and return to positive growth rate
- Operating cash flow and free cash flow to assess path to cash flow breakeven
- Cash and equivalents levels and monthly burn rate relative to runway
- Gross margin when reportable to understand unit economics and product viability
- Operating expense reduction initiatives to achieve operating profitability timeline
DNABW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.92x current ratio provides a solid financial cushion.
DNABW Profitability Ratios
DNABW vs Healthcare Sector
How Ginkgo Bioworks Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DNABW Overvalued or Undervalued?
Based on fundamental analysis, Ginkgo Bioworks Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DNABW Balance Sheet & Liquidity
DNABW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Ginkgo Bioworks Holdings, Inc.'s revenue has declined by 20% over the 5-year period, indicating business contraction. The most recent EPS of $-18.37 indicates the company is currently unprofitable.
DNABW Growth Metrics (YoY)
DNABW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $38.8M | -$56.4M | $-1.08 |
| Q2 2025 | $49.6M | N/A | $-1.10 |
| Q1 2025 | $37.9M | N/A | $-1.68 |
| Q3 2024 | $55.4M | -$56.4M | $-1.08 |
| Q2 2024 | $56.2M | -$173.3M | $-0.09 |
| Q1 2024 | $37.9M | N/A | $-0.08 |
| Q3 2023 | $55.4M | -$302.9M | $-0.16 |
| Q2 2023 | $80.6M | -$173.3M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DNABW Capital Allocation
DNABW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Ginkgo Bioworks Holdings, Inc. (CIK: 0001830214)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DNABW
What is the AI rating for DNABW?
Ginkgo Bioworks Holdings, Inc. (DNABW) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DNABW's key strengths?
Claude: Strong liquidity position with $167.2M cash and 4.92x current ratio provides runway for operations. Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk.
What are the risks of investing in DNABW?
Claude: Severe operating losses of -$315.3M with -185.3% operating margin indicate business is far from profitability. Revenue declined 25.1% year-over-year despite being pre-commercial, suggesting market execution challenges.
What is DNABW's revenue and growth?
Ginkgo Bioworks Holdings, Inc. reported revenue of $170.2M.
Does DNABW pay dividends?
Ginkgo Bioworks Holdings, Inc. does not currently pay dividends.
Where can I find DNABW SEC filings?
Official SEC filings for Ginkgo Bioworks Holdings, Inc. (CIK: 0001830214) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DNABW's EPS?
Ginkgo Bioworks Holdings, Inc. has a diluted EPS of $-5.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DNABW a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Ginkgo Bioworks Holdings, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DNABW stock overvalued or undervalued?
Valuation metrics for DNABW: ROE of -61.5% (sector avg: 15%), net margin of -183.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DNABW stock in 2026?
Our dual AI analysis gives Ginkgo Bioworks Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DNABW's free cash flow?
Ginkgo Bioworks Holdings, Inc.'s operating cash flow is $-171.1M, with capital expenditures of $7.7M. FCF margin is -105.0%.
How does DNABW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -183.8% (avg: 12%), ROE -61.5% (avg: 15%), current ratio 4.92 (avg: 2).